QW48-August 2025

Question: Select each option to validate with explanations

Clinical Case Scenario

A 68-year-old male is admitted to the intensive care unit with septic shock due to severe community-acquired pneumonia and hypoxemic respiratory failure. He is hemodynamically stabilized on norepinephrine at 0.15 mcg/kg/min and has received an initial 30 mL/kg of crystalloid fluids, followed by an additional 3 liters of crystalloid over the next 24 hours, guided by pulse pressure variation monitoring. After 24 hours, the following data is available:

Serum Creatinine: 0.9 mg/dL (baseline: 0.8 mg/dL)
Urine Output: 1.2 mL/kg/hr over the past 6 hours
Arterial Blood Gas: pH 7.38, PaO₂ 85 mmHg, PaCO₂ 39 mmHg, HCO₃⁻ 24 mmol/L, lactate 2.2 mmol/L
NGAL (Neutrophil Gelatinase-Associated Lipocalin): 220 ng/mL (normal: <150 ng/mL)
TIMP2·IGFBP7 (combined value): 0.9 (high-risk threshold >0.3)

Based on above information, tick one best response from each question:

Question 1a. What is the most appropriate interpretation of this patient’s renal profile?

A. The patient has no risk of acute kidney injury (AKI) due to normal creatinine and urine output.

B. The patient has subclinical AKI, which may indicate early kidney damage despite normal traditional markers.

C. The elevated biomarkers are likely false positives and do not require further investigation.

D. The patient has chronic kidney disease (CKD) rather than acute kidney injury.

Wrong Answer: A. The patient has no risk of acute kidney injury (AKI) due to normal creatinine and urine output.

Right Answer: B. The patient has subclinical AKI, which may indicate early kidney damage despite normal traditional markers.

Explaination:
Subclinical AKI is defined as biomarker-positive, creatinine-negative AKI, which suggests early tubular damage or stress before overt dysfunction. Elevated NGAL indicates tubular injury, while TIMP2·IGFBP7 reflects cell cycle arrest signaling impending AKI. Studies show patients in this profile are at increased risk for long-term renal decline and mortality, emphasizing the utility of biomarkers in early detection and risk stratification, especially in septic contexts.[1]

Wrong Answer: C. The elevated biomarkers are likely false positives and do not require further investigation.

Wrong Answer: D. The patient has chronic kidney disease (CKD) rather than acute kidney injury.

Question 1b: What is the most appropriate interpretation regarding the need for renal replacement therapy (RRT) in this patient?

A. RRT should be initiated immediately based on elevated NGAL levels.

B. TIMP2·IGFBP7 suggests high risk for AKI progression, but clinical indicators should guide RRT initiation.

C. Serum creatinine and urine output are sufficient to decide RRT initiation, and biomarkers are not necessary.

D. Neither NGAL nor TIMP2·IGFBP7 are reliable predictors for RRT in septic AKI.

Wrong Answer: A. RRT should be initiated immediately based on elevated NGAL levels.

Right Answer: B. TIMP2·IGFBP7 suggests high risk for AKI progression, but clinical indicators should guide RRT initiation.

Explaination:
TIMP2·IGFBP7 is a strong predictor of AKI progression and adverse outcomes, including the need for RRT. However, RRT initiation should be guided by clinical indicators such as persistent hyperkalemia, severe metabolic acidosis, or fluid overload unresponsive to medical therapy.[2,3] Elevated NGAL indicates tubular injury but does not independently mandate RRT initiation. Biomarker Comparison: NGAL vs. TIMP2·IGFBP7

Biomarker	Mechanism	Predictive Role for RRT	Strengths	Limitations
NGAL (Neutrophil Gelatinase-Associated Lipocalin)	Released by injured tubular cells; reflects early tubular damage	Meta-analyses show NGAL is a fair predictor for RRT initiation and moderate predictor for RRT liberation	- Early rise post-injury - Available in plasma and urine - Correlates with severity	- Influenced by systemic inflammation - Cut-off values vary widely
TIMP2·IGFBP7 (Cell cycle arrest markers)	Indicate G1 cell cycle arrest in stressed tubular cells	Shown to predict risk of AKI progression, mortality, and need for RRT, especially in septic and surgical patients	- FDA-approved - Strong prognostic value - Better performance in high-risk ICU cohorts	- Less specific for injury type - Moderate AUC for RRT prediction (e.g., ~0.67 in pediatric AKI)

Which AKI biomarkers (amongst all available) has been demonstrated to be strongly predictive of RRT initiation/requirement? Several AKI biomarkers have shown promise in predicting the need for renal replacement therapy (RRT), with plasma and urinary NGAL, urinary TIMP-2 x IGFBP-7, and suPAR being among the most studied. While these biomarkers can be helpful, clinical judgment and other factors (like serum creatinine, diuresis, and SOFA score) remain crucial for RRT decision-making.[4] Nephro-critical care pearls

NGALmay be more sensitive to early tubular injury, making it useful for timing RRT initiation, especially in severe AKI.
TIMP2·IGFBP7excels in risk stratification and predicting adverse outcomes, including mortality and dialysis need, particularly in critically ill adults and children.
Some studies suggest combining both biomarkers with clinical indicators (e.g. urine output, lactate) enhances predictive accuracy.

Wrong Answer: C. Serum creatinine and urine output are sufficient to decide RRT initiation, and biomarkers are not necessary.

Wrong Answer: D. Neither NGAL nor TIMP2·IGFBP7 are reliable predictors for RRT in septic AKI.

Reference:

1. Zou C, Wang C, Lu L. Advances in the study of subclinical AKI biomarkers. Front Physiol. 2022 Aug 24;13:960059. doi: 10.3389/fphys.2022.960059.
2. Albert C, Haase M, Albert A, Zapf A, Braun-Dullaeus RC, Haase-Fielitz A. Biomarker-Guided Risk Assessment for Acute Kidney Injury: Time for Clinical Implementation? Ann Lab Med. 2021 Jan;41(1):1-15. doi: 10.3343/alm.2021.41.1.1.
3. Ostermann, M., Legrand, M., Meersch, M. et al. Biomarkers in acute kidney injury. Ann. Intensive Care 14, 145 (2024). https://doi.org/10.1186/s13613-024-01360-9
4. Xu, Q., Zhou, Z., Jin, L. et al. Novel biomarkers for predicting successful liberation of renal replacement therapy for acute kidney injury: a systematic review. Crit Care 29, 213 (2025). https://doi.org/10.1186/s13054-025-05451-2

Name

This field is for validation purposes and should be left unchanged.